Immunohistochemical characteristics of diffuse sclerosing variant of papillary carcinoma: Comparison with conventional papillary carcinoma

APMIS

Volumn 118, Issue 10, 2010, Pages 744-752

  Koo, Ja Seung ^a   Shin, Eunah ^b   Hong, Soon Won ^a,c  

^a Yonsei University College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

carcinoma; Diffuse sclerosing; immunohistochemistry; papillary; thyroid gland

Indexed keywords

BETA CATENIN; CD15 ANTIGEN; CD56 ANTIGEN; CYTOKERATIN 19; GALECTIN 3; PROTEIN BCL 2; PROTEIN P53; PROTEIN P63; UVOMORULIN;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CHILD; CLINICAL FEATURE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; THYROID PAPILLARY CARCINOMA; TISSUE MICROARRAY; TUMOR RECURRENCE; ADOLESCENT; COMPARATIVE STUDY; METABOLISM; MIDDLE AGED; PAPILLARY CARCINOMA; PATHOLOGY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; THYROID TUMOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CARCINOMA, PAPILLARY; CHILD; FEMALE; GALECTIN 3; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; TISSUE ARRAY ANALYSIS; YOUNG ADULT;

EID: 77956924338     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2010.02653.x     Document Type: Article

References (30)

1. Carcangiu ML, Bianchi S. Diffuse sclerosing variant of papillary thyroid carcinoma. Clinicopathologic study of 15 cases. Am J Surg Pathol 1989 13 : 1041 9.
2. Chow SM, Chan JK, Law SC, Tang DL, Ho CM, Cheung WY, et al. Diffuse sclerosing variant of papillary thyroid carcinoma - clinical features and outcome. Eur J Surg Oncol 2003 29 : 446 9.
3. Falvo L, Giacomelli L, D'Andrea V, Marzullo A, Guerriero G, de Antoni E. Prognostic importance of sclerosing variant in papillary thyroid carcinoma. Am Surg 2006 72 : 438 44.
4. Fujimoto Y, Obara T, Ito Y, Kodama T, Aiba M, Yamaguchi K. Diffuse sclerosing variant of papillary carcinoma of the thyroid. Clinical importance, surgical treatment, and follow-up study. Cancer 1990 66 : 2306 12.
5. Lam AK, Lo CY. Diffuse sclerosing variant of papillary carcinoma of the thyroid: a 35-year comparative study at a single institution. Ann Surg Oncol 2006 13 : 176 81.
6. Soares J, Limbert E, Sobrinho-Simoes M. Diffuse sclerosing variant of papillary thyroid carcinoma. A clinicopathologic study of 10 cases. Pathol Res Pract 1989 185 : 200 6.
7. Thompson LD, Wieneke JA, Heffess CS. Diffuse sclerosing variant of papillary thyroid carcinoma: a clinicopathologic and immunophenotypic analysis of 22 cases. Endocr Pathol 2005 16 : 331 48.
8. Sheu SY, Schwertheim S, Worm K, Grabellus F, Schmid KW. Diffuse sclerosing variant of papillary thyroid carcinoma: lack of BRAF mutation but occurrence of RETPTC rearrangements. Mod Pathol 2007 20 : 779 87.
9. Schroder SSW, Rehpenning W. Prognostic significance of Leu-M1 immunostaing in papillary carcinoma of the thyroid gland.
10. Yamamoto Y, Izumi K, Otsuka H. An immunohistochemical study of epithelial membrane antigen, cytokeratin, and vimentin in papillary thyroid carcinoma. Recognition of lethal and favorable prognostic types. Cancer 1992 70 : 2326 33.
11. Godballe C, Asschenfeldt P, Jorgensen KE, Bastholt L, Clausen PP, Hansen TP, et al. Prognostic factors in papillary and follicular thyroid carcinomas: p53 expression is a significant indicator of prognosis. Laryngoscope 1998 108 : 243 9.
12. von Wasielewski R, Rhein A, Werner M, Scheumann GF, Dralle H, Potter E, et al. Immunohistochemical detection of E-cadherin in differentiated thyroid carcinomas correlates with clinical outcome. Cancer Res 1997 57 : 2501 7.
13. Barroeta JE, Baloch ZW, Lal P, Pasha TL, Zhang PJ, LiVolsi VA. Diagnostic value of differential expression of CK19, Galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: an immunohistochemical tissue microarray analysis. Endocr Pathol 2006 17 : 225 34.
14. Park YJ, Kwak SH, Kim DC, Kim H, Choe G, Park do J, et al. Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules. J Korean Med Sci 2007 22 : 621 8.
15. Levrero M, De Laurenzi V, Costanzo A, Gong J, Wang JY, Melino G. The p53p63p73 family of transcription factors: overlapping and distinct functions. J Cell Sci 2000 113 (Pt 10 1661 70.
16. Reis-Filho JS, Schmitt FC. Taking advantage of basic research: p63 is a reliable myoepithelial and stem cell marker. Adv Anat Pathol 2002 9 : 280 9.
17. Di Como CJ, Urist MJ, Babayan I, Drobnjak M, Hedvat CV, Teruya-Feldstein J, et al. p63 expression profiles in human normal and tumor tissues. Clin Cancer Res 2002 8 : 494 501.
18. Malaguarnera R, Mandarino A, Mazzon E, Vella V, Gangemi P, Vancheri C, et al. The p53-homologue p63 may promote thyroid cancer progression. Endocr Relat Cancer 2005 12 : 953 71.
19. Kim YW, Do IG, Park YK. Expression of the GLUT1 glucose transporter, p63 and p53 in thyroid carcinomas. Pathol Res Pract 2006 202 : 759 65.
20. Preto A, Reis-Filho JS, Ricardo S, Soares P. p63 expression in papillary and anaplastic carcinomas of the thyroid gland: lack of an oncogenetic role in tumorigenesis and progression. Pathol Res Pract 2002 198 : 449 54.
21. Bolat F, Kayaselcuk F, Nursal TZ, Reyhan M, Bal N, Yildirim S, et al. Histopathological changes in thyroid tissue after fine needle aspiration biopsy. Pathol Res Pract 2007 203 : 641 5.
22. Noh SJ, Cha EJ, Choi KH, Moon WS. Papillary carcinoma of the thyroid with massive squamous metaplasia after fine needle aspiration: a potential diagnostic pitfall. Acta Cytol 2009 53 : 605 7.
23. Polyzos SA, Patsiaoura K, Zachou K. Histological alterations following thyroid fine needle biopsy: a systematic review. Diagn Cytopathol 2009 37 : 455 65.
24. Fletcher CDM. Diagnostic Histopathology of Tumors, 3rd edn.
25. El Demellawy D, Nasr A, Alowami S. Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid. Diagn Pathol 2008 3 : 5.
26. Unger P, Ewart M, Wang BY, Gan L, Kohtz DS, Burstein DE. Expression of p63 in papillary thyroid carcinoma and in Hashimoto's thyroiditis: a pathobiologic link? Hum Pathol 2003 34 : 764 9.
27. Turkoz HK, Oksuz H, Yurdakul Z, Ozcan D. Galectin-3 expression in tumor progression and metastasis of papillary thyroid carcinoma. Endocr Pathol 2008 19 : 92 6.
28. Siironen P, Nordling S, Louhimo J, Haapiainen R, Haglund C. Immunohistochemical expression of Bcl-2, Ki-67, and p21 in patients with papillary thyroid cancer. Tumour Biol 2005 26 : 50 6.
29. Aksoy M, Giles Y, Kapran Y, Terzioglu T, Tezelman S. Expression of bcl-2 in papillary thyroid cancers and its prognostic value. Acta Chir Belg 2005 105 : 644 8.
30. Haynik DM, Prayson RA. Immunohistochemical expression of Bcl-2, Bcl-x, and Bax in follicular carcinomas of the thyroid. Appl Immunohistochem Mol Morphol 2006 14 : 417 21.